Opko Health Inc. (OPK)
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.
OPKO Health: Mazdutide And MDX-2201 Could Change Everything
On July 27, OPKO Health, Inc. released its Q2 numbers. So, OPK's revenue from transfer of IP and other increased 208% YoY to $46.1 million in Q2, driven by a Nicoya license amendment. Also, OPKO raised its full-year 2026 revenue guidance from $530-$560 million to $560-$585 million.
OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know
OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript
Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
